What are the Historical Developments and Current Growth Metrics of the Nivolumab Market?
The nivolumab market has seen considerable growth due to a variety of factors.
• The market size of nivolumab has seen a swift expansion in the past few years. The market is projected to increase from $1.69 billion in 2024 to $1.94 billion in 2025, with a compound annual growth rate (CAGR) of 14.7%.
This growth over the historical period is linked to advancements in immunotherapy, heightened occurrence of cancer, successful clinical trials, along with regulatory approvals.
What is the Forecasted Market Size and CAGR for the Nivolumab Market?
The nivolumab market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for nivolumab is projected to experience swift expansion in the upcoming years, reaching an estimated $3.2 billion in 2029 and a compound annual growth rate (CAGR) of 13.4%.
The expected growth during the forecast period can be credited to factors such as individualized medical treatments, developing indications, global availability of cancer treatments, and improvements in combined therapies. Key trends to look out for in the forecast period encompass biomarker-guided treatments, neoantigen vaccines, improved immunotherapy schedules, and prolonged follow-up studies.
What Key Factors and Trends Are Driving The Growth Nivolumab Market?
An upward trend in cancer cases is anticipated to spur the expansion of the nivolumab market. Cancer is a broad term for diseases that can emerge in nearly every organ or tissue in the body when abnormal cells expand uncontrollably, exceed their normal boundaries, and metastasize to other organs or invade surrounding tissues. Nivolumab aids in the management and treatment of various kinds of cancer by preventing the cancer cells from inhibiting the immune system, enabling the immune system to assault and destroy the cancer cells. For example, data from the Australian Institute of Health and Welfare, a government body in Australia that focuses on providing detailed health and welfare data and analysis, highlights an increase in the number of cancer diagnoses from 156,781 in 2021 to 160,570 in 2022 – an increase of 3,789 cases in a one-year interval. Consequently, the increasing prevalence of cancer contributes to the expansion of the nivolumab market. Nivolumab Market Driver: Rise in Instances of Non-Small Cell Lung Cancer (NSCLC) Fuels Nivolumab Market Expansion
What Are The Market Segments In The Nivolumab Market?
The nivolumab market covered in this report is segmented –
1) By Type: Injection 4mL, Injection 10mL
2) By Route Of Administration: Intravenous, Other Routes Of Administration
3) By Application: Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications
4) By End-User: Clinic, Hospital, Other End-Users
Subsegments:
1) By Injection 4mL: Single-Dose Vial, Multi-Dose Vial
2) By Injection 10mL: Single-Dose Vial, Multi-Dose Vial
Pre-Book The Nivolumab Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Nivolumab Market?
Leading firms in the nivolumab market are channelizing their efforts towards the creation of novel drugs to serve their clients better and maintain their market position. The formulation of new drug treatments can enhance recovery prospects for patients suffering from various illnesses. For example, in May 2022, the U.S. Food and Drug Administration (FDA) sanctioned two nivolumab-based treatments from Bristol-Myers Squibb Co. - an American pharmaceutical corporation majorly working on cancer, cardiovascular, immunology, and fibrotic healing programs. These treatments involve the use of Nivolumab combined with fluoropyrimidine and platinum-containing chemotherapy, and Nivolumab alongside Yervoy (ipilimumab). They are prescribed as the primary treatment for adults with advanced or metastatic esophageal squamous cell carcinoma (ESCC) that cannot be surgically removed, irrespective of their PD-L1 status.
Who Are the Key Players In The Nivolumab Market?
Major companies operating in the nivolumab market are:
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• AbbVie Inc.
• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Chugai Pharmaceutical Co. Ltd.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Ono Pharmaceutical Co. Ltd.
• Kyowa Kirin Co. Ltd.
• Nippon Kayaku Co. Ltd.
• Luye Pharma AG
• Genentech Inc.
• Taiho Pharmaceutical Co. Ltd.
• SymBio Pharmaceuticals Ltd.
• Xbrane Biopharma AB
• NeuClone Therapeutics Inc.
What Are The Regional Insights Into The Nivolumab Market?
North America was the largest region in the nivolumab market in 2024. The regions covered in nivolumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
